Biogen Inc. (LON:0R1B)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 16.52B |
| Revenue (ttm) | 7.30B |
| Net Income (ttm) | 1.12B |
| Shares Out | n/a |
| EPS (ttm) | 7.63 |
| PE Ratio | 14.79 |
| Forward PE | 9.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,850 |
| Average Volume | 3,703 |
| Open | 150.24 |
| Previous Close | 148.83 |
| Day's Range | 149.72 - 151.56 |
| 52-Week Range | 110.20 - 187.45 |
| Beta | 0.13 |
| RSI | 58.63 |
| Earnings Date | Oct 30, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprote...
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
On Friday, Biogen Inc . (NASDAQ: BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthen...
Biogen (BIIB) Secures Licensing Deal for Immunology Candidate
Biogen (BIIB) Secures Licensing Deal for Immunology Candidate
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Biogen, Vanqua ink licensing deal worth up to $1B for immunology drug
Biogen (BIIB) Secures Global Rights in $1.06 Billion Deal with Vanqua
Biogen (BIIB) Secures Global Rights in $1.06 Billion Deal with Vanqua
Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion
Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to expand its pipeline of immunology drugs.
Biogen Inks License Deal For Vanqua Bio's Oral C5aR1 Antagonist
(RTTNews) - Biogen Inc. (BIIB), Friday announced a license agreement granting the company exclusive worldwide rights to Chicago-based Vanqua Bio's preclinical, oral C5aR1 antagonist, which is designed...
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's pr...
Biogen (BIIB) Highlights Promising Results of Dapirolizumab Pegol in Lupus Studies
Biogen (BIIB) Highlights Promising Results of Dapirolizumab Pegol in Lupus Studies
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug...
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Key PointsFlorida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter.
Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy
Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy
Patient Opportunity Equity strategy buys UNH, CROX, MAT, IAC, and BIIB
Why InnoCare's Licensing Deal Triggered A Stock Rout
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print Key Takeaways: The counterparty, Zenas ...
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact
Biogen sees negative impact on Q3 EPS from IPR&D expense
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
TOKYO and CAMBRIDGE, Mass. , Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Headquarters: Cambridge, Massachusetts , C...
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CE...
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BIIB Stock News
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BIIB Stock News
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome
(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorevunersen, reinforcing its potential as a ...
BIIB: New Findings Highlight the Potential of Zorevunersen for Dravet Syndrome
BIIB: New Findings Highlight the Potential of Zorevunersen for Dravet Syndrome
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Syndrome
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Syndrome
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal c...
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...